CervoMed will present 12-week NfL and GFAP biomarker data from its Phase 2a neflamapimod trial in nfvPPA, a tau-associated form of FTD.
Written By: Anamika Koshti, PharmD
Reviewed By: Pharmacally Editorial Team
CervoMed Inc. will present initial biomarker findings for neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting in Philadelphia on October 11, 2026. The late-breaking oral presentation will report 12-week data for neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) from at least 22 participants in the Phase 2a study.
The company recently completed enrollment in the trial, which included 25 participants across leading academic medical centers in the United States and United Kingdom. The study is evaluating neflamapimod’s safety, pharmacokinetics, and clinical effects in patients with nfvPPA.
Biomarkers May Clarify Disease Activity
Neflamapimod is an investigational oral small molecule that crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 mitogen-activated protein kinase (p38α MAPK).
The target has been implicated in neuroinflammation and synaptic dysfunction, two processes that contribute to neuronal injury and cognitive decline. Peer-reviewed research has also supported p38α as a potential therapeutic target in tau-related neurodegenerative disease.
The upcoming biomarker analysis will focus on NfL and GFAP. NfL is widely used as a blood-based marker of axonal injury, while GFAP reflects astrocytic activation and neuroinflammatory processes. Changes in these biomarkers could provide an early indication of biological effects, although they will need to be interpreted alongside clinical outcomes and longer-term disease measures.
Phase 2a Trial Reaches Full Enrollment
The Phase 2a study (NCT07033481) enrolled 25 people with nfvPPA. The abstract supporting the late-breaking presentation initially included 12-week biomarker data from the first eight participants. The October presentation is expected to expand those findings to at least 22 participants.
The company has not yet disclosed the biomarker results, so the magnitude, direction, and clinical relevance of any changes remain to be determined.
That distinction is important in nfvPPA, where treatment options remain limited. The disease progressively impairs speech production, sentence construction, and comprehension of complex language and can eventually lead to loss of speech. Patients may also develop problems with planning, judgment, and movement as the disease advances.
CervoMed estimates that 10,000 to 15,000 people in the U.S. and 15,000 to 20,000 in the European Union live with nfvPPA.
Upcoming ISFTD Presentation
The late-breaking oral presentation, titled Initial Biomarker Results from a Phase 2a Clinical Trial of Neflamapimod in Patients with Nonfluent Variant Primary Progressive Aphasia, is scheduled for the Plenary 6 Hot Topics session on October 11 from 8:30 to 10:30 a.m. ET.
NfvPPA is the FTD subtype most commonly associated with tau pathology, making the disease a potentially relevant setting for evaluating therapies directed at mechanisms implicated in tau-driven neurodegeneration.
Neflamapimod received U.S. FDA Orphan Drug Designation for FTD in 2024. The drug is also being studied in dementia with Lewy bodies (NCT05869669) and recovery following ischemic stroke.
The forthcoming biomarker readout will provide an early assessment of biological activity in nfvPPA. Longer-term clinical data will be needed to determine whether any biomarker changes translate into meaningful effects on language function or disease progression.
References
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026, CERVOMED, 10 September 2026
About the Writer
Anamika Koshti (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, and evidence-based medicine. She has authored peer-reviewed publications on Alzheimer’s disease and PCOS, presented research at national conferences, and gained hands-on experience in medical content development and clinical data interpretation. She is committed to translating complex medical research into accurate, accessible content for healthcare professionals and patients.